ELUTIA INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ELUTIA INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.60M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $6.72M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $11.05M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $11.64M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $19.02M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $20.56M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $19.77M | Mar 15, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.38M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($53.95M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($37.66M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($32.90M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($24.83M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($21.83M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($11.94M) | Mar 15, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.91M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($30.71M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($30.53M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($35.19M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($23.03M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($13.60M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($8.41M) | Mar 15, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.16M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.00M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $4.40M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $7.73M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $9.27M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $5.95M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $2.40M | Mar 15, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.81M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($22.66M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($21.76M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($21.43M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($15.45M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($13.63M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($7.23M) | Mar 15, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.88M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $654.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $346.0K | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $540.0K | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $369.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $640.0K | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $577.0K | Mar 15, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.35M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $36.13M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $43.43M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $68.84M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $67.17M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $82.81M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $44.77M | Mar 15, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.68M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $82.39M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $82.03M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $73.87M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $53.65M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $61.98M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $55.43M | Mar 15, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.67M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($46.26M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | ($38.60M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | ($5.03M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2021 | $13.52M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $20.83M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($55.11M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | ($43.41M) | Mar 15, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($176.21M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($229.59M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($175.64M) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | ($137.99M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($105.09M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($80.26M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($56.94M) | Mar 15, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.35M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $13.24M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $19.28M | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | $16.99M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $30.39M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $39.15M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $2.48M | Mar 15, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $18.47M | Mar 8, 2022 |
| FY2020 | Dec 31, 2020 | $24.12M | Mar 15, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (8) | Mar 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 11, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (8) | Mar 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | 648,277 | Mar 15, 2021 |